Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service incontinence, prolapse & sacral neuromodulation cases in Nebraska: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (219 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 11 | 940 | 18% |
| 2020 | 9 | 918 | 22% |
| 2021 | 9 | 920 |
Slings, artificial sphincter, colpopexy, sacral neuromodulation, penile prosthesis. Professional codes (what the surgeon bills): CPT 57288, 53440, 53445, 57425, 57282, 57283, 64581, 64590, 54405.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 96% of the cases CMS names in Nebraska; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 35 | 1,512−0.1%/yr | −0.1%/yr | 5.81.1× | 12% | 1,880 in 2030+3.7%/yr |
| BPH procedures |
Incontinence, prolapse & sacral neuromodulation in every state, and its device makers · Every procedure market in Nebraska · Every state · Compare with Ohio
| 2024 |
| 849 |
| 37% |
| 2025 est. | ≈ 920 | – |
| 2026 est. | ≈ 950 | – |
| 27% |
| 2022 | 8 | 777 | 31% |
| 2023 | 11 | 946 | 35% |
| 2024 | 12 | 849 | 37% |
| 2025 from claims | – | 922 745–1,083 | 37% |
| 2026 forecast | – | 946 741–1,188 | 37% |
| 2027 forecast | – | 964 715–1,274 | 37% |
| 2028 forecast | – | 983 696–1,357 | 38% |
| 2029 forecast | – | 1,002 681–1,437 | 38% |
| 2030 forecast | – | 1,021 669–1,516 | 38% |
In 2025, 76% hospital outpatient, 24% surgery center. The share outside the hospital has moved −5 pts since 2019.
| 2,574−0.2%/yr |
| −0.2%/yr |
| 1.9 |
| 8% |
| 3,390 in 2030+4.7%/yr |
| Michigan | 25 | 1,789−6.7%/yr | −6.7%/yr | 2.1 | 4% | 1,480 in 2030−3.1%/yr |
| Indiana | 18 | 1,755−4.5%/yr | −4.5%/yr | 2.5 | 16% | 1,650 in 2030−1%/yr |
| Missouri | 21 | 1,596−2.3%/yr | −2.3%/yr | 2.6 | 10% | 1,480 in 2030−1.2%/yr |
| Minnesota | 16 | 1,110+0.9%/yr | +0.9%/yr | 2.4 | 7% | 1,930 in 2030+9.7%/yr |
| Wisconsin | 13 | 1,066+0.3%/yr | +0.3%/yr | 1.9 | 3% | 1,370 in 2030+4.2%/yr |
| Kansas | 15 | 1,028−2.4%/yr | −2.4%/yr | 2.5 | 21% | 990 in 2030−0.6%/yr |
| Iowa | 7 | 604−0.6%/yr | −0.6%/yr | 1.4 | 14% | 600 in 2030−0.1%/yr |
| South Dakota | 4 | 4160%/yr | 0%/yr | 3.2 | 0% | 540 in 2030+4.4%/yr |
| 20 |
| 1,469−17%/yr |
| −17%/yr |
| 5.61.2× |
| 29% |
| 1,250 in 2030−2.7%/yr |
| Hysterectomy, hysteroscopy & ablation | 4 | 529−3.8%/yr | −3.8%/yr | 2.20.7× | 9% | 650 in 2030+3.6%/yr |
| Prostatectomy & nephrectomy | 9 | 452+0.8%/yr | +0.8%/yr | 1.81.3× | 0% | 520 in 2030+2.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Coloplast leads with 45% of company spending on these surgeons in 2025, +26 pts on 2024.
In 2025, 7 companies reported engagement with Nebraska’s surgeons worth $19K in consulting, speaking, meals and travel tied to these products, about $1,600 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.